Hodgkin's disease after transplantation. 1996

J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
Inserm U80, Service d'Urologie, Département d' Hématologie, Hôpital Edouard Herriot, Lyon, France.

Hodgkin's disease (HD) has seldom been reported after transplantation. Epstein-Barr virus (EBV) is present in about 50% of Reed-Sternberg cells in HD developing in immunocompetent individuals, but is more frequently found in HD of acquired immune deficiency syndrome patients. We report 7 cases of HD that occurred in transplant recipients. Clinical and pathological data and studies of EBV reveal specific features of HD after transplantation. Six patients received kidney transplants and 1 patient received combined kidney and pancreas transplantation. Immunosuppressive therapy consisted of cyclosporine, steroids, azathioprine, and antilymphocyte globulins. One patient received, in addition, anti-CD3 mAb therapy and an EBV+ B cell lymphoma developed. Retrospective EBV serological data from patients were collected. Tumors were classified according to pathology. EBV studies were conducted by immunohistochemical methods with monoclonal antibodies to EBV-latent membrane protein (LMP) or EBV-nuclear antigen 2 (EBNA2), and by in situ hybridization for latent nuclear EBV-early RNAs (EBERs). The mean lapse of time between transplantation and HD was 49 months. Six patients presented with enlarged lymph nodes and 1 patient presented with liver involvement. HD was classified as IA in 2 patients, IIA in 3 patients, IIIB in 1 patient, and IVB in 1 patient. Four patients had primary EBV infection after graft, before HD, and the others reactivated latent EBV infection. Histological subtypes were mixed cellularity in 6 cases and lymphocytic depletion in 1 case. Latent EBV infection was detected with EBERs in all tumors. Reed-Sternberg cells expressed LMP, and were negative for EBNA2 expression. Six patients were treated: 2 patients at stage I received radiotherapy, and relapsed within 1 year with a more advanced stage of HD; chemotherapy was indicated as primary therapy in 5 patients, and as salvage therapy in 2 patients; it was associated with radiotherapy in 4 patients. Immunosuppressive therapy was reduced in all patients. Four patients were alive and in complete remission 18, 25, 31, and 67 months after chemotherapy, with a functioning graft in 3 patients. Two patients died of infection. Mixed cellularity is the most frequent histological subtype observed in HD occurring in transplant patients. EBV is present in all Reed-Sternberg cells. Posttransplant HD shows similarities with human immunodeficiency virus-associated HD. These facts argue for a role of EBV infection and immunosuppression in the progression of HD after transplantation.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal

Related Publications

J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
January 1997, American journal of clinical pathology,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
April 2006, Transplant international : official journal of the European Society for Organ Transplantation,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
June 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
October 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
February 1977, American journal of surgery,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
January 1992, Bone marrow transplantation,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
March 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
April 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
April 1995, Transplantation proceedings,
J L Garnier, and Y Lebranchu, and J Dantal, and J Bedrossian, and R Cahen, and D Assouline, and A Jaccard, and F Fetissoff, and A Moreau, and X Martin, and G Delsol, and F Berger, and J L Touraine
January 1994, Biotechnology therapeutics,
Copied contents to your clipboard!